Alcon Inc. (SWX:ALC)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 30.69B |
| Revenue (ttm) | 8.12B |
| Net Income (ttm) | 834.86M |
| Shares Out | 491.20M |
| EPS (ttm) | 1.67 |
| PE Ratio | 37.31 |
| Forward PE | 23.91 |
| Dividend | 0.28 (0.44%) |
| Ex-Dividend Date | May 13, 2025 |
| Volume | 809,681 |
| Average Volume | 1,153,001 |
| Open | 63.02 |
| Previous Close | 63.24 |
| Day's Range | 62.42 - 63.36 |
| 52-Week Range | 57.68 - 87.00 |
| Beta | 0.69 |
| RSI | 52.64 |
| Earnings Date | Feb 26, 2026 |
About Alcon
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. It operates through two segments, Surgical and Vision Care. The company offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, Verion reference unit and Verion digital marker, ... [Read more]
Financial Performance
In 2024, Alcon's revenue was $9.91 billion, an increase of 4.82% compared to the previous year's $9.46 billion. Earnings were $1.02 billion, an increase of 4.52%.
Financial numbers in USD Financial StatementsNews
STAAR Surgical (STAA) Gains as ISS Backs Alcon's Improved Offer
STAAR Surgical (STAA) Gains as ISS Backs Alcon's Improved Offer
STAAR Surgical gains as proxy adviser ISS supports revised Alcon deal
STAAR Surgical shares jump after ISS backs Alcon's $30.75 buyout offer. Discover key shareholder moves and what this means ahead of the Dec. 19 vote.
Staar Surgical Endorses Alcon (ALC) Merger, Backed by New ISS Report
Staar Surgical Endorses Alcon (ALC) Merger, Backed by New ISS Report
STAAR Surgical (STAA) Faces Investor Pushback on Alcon Offer
STAAR Surgical (STAA) Faces Investor Pushback on Alcon Offer
STAAR Surgical falls as proxy adviser recommends against revised Alcon deal
Broadwood Partners: Leading Proxy Advisory Firm Glass Lewis Reaffirms Recommendation “AGAINST” STAAR Surgical Sale to Alcon
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today announced that Glass, Lewis & Co., LLC (“Glass Lewis”), a leading independent proxy advisory firm, ha...
Alcon (ALC) Sees Downgrade, Shares Drop 1.6%
Alcon (ALC) Sees Downgrade, Shares Drop 1.6%
Alcon (ALC) Faces Downgrade Amid Earnings Concerns
Alcon (ALC) Faces Downgrade Amid Earnings Concerns
Alcon draws double downgrade at BofA on earnings growth risk
Alcon Just Got Hit With Its First Bearish Call Since August
Alcon Just Got Hit With Its First Bearish Call Since August
Alcon (ALC) Involved in STAAR's Assertive Response to Merger Misconceptions
Alcon (ALC) Involved in STAAR's Assertive Response to Merger Misconceptions
STAAR Surgical Sets the Record Straight Regarding its Robust Go-Shop Process
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, toda...
Concerns Arise Over Alcon's Proposed Acquisition of Staar Surgical (ALC)
Concerns Arise Over Alcon's Proposed Acquisition of Staar Surgical (ALC)
Broadwood Partners Comments on STAAR Surgical Board Dissent on the Revised Sale to Alcon
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood,” “we,” “us” or “our”) today reacted to the proxy statement supplement filed by STAAR Surgical Company ...
STAAR Surgical's Top Investors Reject Sweetened Alcon Offer, Cite Flawed Sale Process
Yunqi Capital Limited, which holds a 5.1% stake in STAAR Surgical Company (NASDAQ: STAA), issued a letter to shareholders on Wednesday. Staar Surgical shares are sliding. What's pressuring STAA stock...
STAAR Surgical's Top Investors Reject Sweetened Alcon Offer, Cite Flawed Sale Process
Yunqi Capital Limited, which holds a 5.1% stake in STAAR Surgical Company (NASDAQ: STAA), issued a letter to shareholders on Wednesday.
STAAR Surgical holder Yunqi Capital still against sale to Alcon
Get the latest on STAAR Surgical's sale bid as key shareholders oppose Alcon's increased offer. Learn why investors are pushing back.
Alcon (ALC) Acquisition Proposal Faces Opposition from Major Shareholder
Alcon (ALC) Acquisition Proposal Faces Opposition from Major Shareholder
STAAR Surgical: Alcon Raises Its Bid, But Obstacles Remain
Get the latest on Alcon's increased buyout offer for STAA, shareholder reactions, and market implications.
Yunqi Capital Comments on STAAR Surgical's Go-Shop Process and Alcon's Revised Offer
HONG KONG--(BUSINESS WIRE)--Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Company...
Broadwood Partners Challenges Alcon's (ALC) Acquisition of Staar Surgical
Broadwood Partners Challenges Alcon's (ALC) Acquisition of Staar Surgical
Broadwood Partners Responds to Alcon's Increase to Proposed Acquisition Price of STAAR Surgical
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood,” “we,” “us” or “our”) today responded to the amended transaction terms of the proposed acquisition of ...
Alcon Announces Renewed STAAR Surgical Acquisition Deal At $30.75/Share In Cash
(RTTNews) - Alcon Inc. (ALC), Tuesday announced an amended merger agreement for the acquisition of STAAR Surgical Company (STAA), intending to purchase outstanding stock of the latter for $30.75 per s...
Alcon lifts bid for medical technology firm Staar to $1.6 billion
Swiss eyecare giant Alcon has lifted its bid to acquire Staar Surgical to $30.75 per share in cash, it said on Tuesday, valuing the medical technology firm at $1.6 billion.
Alcon (ALC) Enhances Offer for Staar Surgical Acquisition
Alcon (ALC) Enhances Offer for Staar Surgical Acquisition